British Journal of Cancer - Table of Contents alert Volume 116 Issue 10

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 116, Issue 10 (1247-1373) Published online 9 May 2017 In this issue Clinical Studies Translational Therapeutics Molecular Diagnostics Epidemiology Also new today Advance online publication Digital Edition Follow us on Twitter Sign up for e-alerts Recommend to your library Web feed Subscribe Clinical Studies Top Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis Uwe Pelzer, Jean-Frédéric Blanc, Davide Melisi, Antonio Cubillo, Daniel D Von Hoff, Andrea Wang-Gillam, Li-Tzong Chen, Jens T Siveke, Yin Wan, Caitlyn T Solem, Marc F Botteman, Yoojung Yang, Floris A de Jong and Richard A Hubner Br J Cancer 2017 116: 1247-1253; advance online publication, March 28, 2017; 10.1038/bjc.2017.67 Abstract | Full Text Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care Anna M Chiarelli, Derek Muradali, Kristina M Blackmore, Courtney R Smith, Lucia Mirea, Vicky Majpruz, Frances P O'Malley, May Lynn Quan and Claire MB Holloway Br J Cancer 2017 116: 1254-1263; advance online publication, March 30, 2017; 10.1038/bjc.2017.87 Abstract | Full Text Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer C N Hurt, S Falk, T Crosby, A McDonald, R Ray, G Joseph, J Staffurth, R A Abrams, G Griffiths, T Maughan and S Mukherjee Br J Cancer 2017 116: 1264-1270; advance online publication, April 4, 2017; 10.1038/bjc.2017.95 Abstract | Full Text Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study Tormod Kyrre Guren, Maria Thomsen, Elin H Kure, Halfdan Sorbye, Bengt Glimelius, Per Pfeiffer, Pia Österlund, Fridbjörn Sigurdsson, Inger Marie Bowitz Lothe, Astrid Marie Dalsgaard, Eva Skovlund, Thoralf Christoffersen and Kjell Magne Tveit Br J Cancer 2017 116: 1271-1278; advance online publication, April 11, 2017; 10.1038/bjc.2017.93 Abstract | Full Text A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation M A Calegari, A Inno, S Monterisi, A Orlandi, D Santini, M Basso, A Cassano, M Martini, T Cenci, I de Pascalis, F Camarda, B Barbaro, L M Larocca, S Gori, G Tonini and C Barone Br J Cancer 2017 116: 1279-1286; advance online publication, April 20, 2017; 10.1038/bjc.2017.109 Abstract | Full Text Translational Therapeutics Top Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study David L Phelps, Jane V Borley, Kirsty J Flower, Roberto Dina, Silvia Darb-Esfahani, Ioana Braicu, Jalid Sehouli, Christina Fotopoulou, Charlotte S Wilhelm-Benartzi, Hani Gabra, Joseph Yazbek, Jayanta Chatterjee, Jacey Ip, Harun Khan, Marina-Therese Likos-Corbett, Robert Brown and Sadaf Ghaem-Maghami Br J Cancer 2017 116: 1287-1293; advance online publication, March 28, 2017; 10.1038/bjc.2017.83 Abstract | Full Text Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium T Goranova, D Ennis, A M Piskorz, G Macintyre, L A Lewsley, J Stobo, C Wilson, D Kay, R M Glasspool, M Lockley, E Brockbank, A Montes, A Walther, S Sundar, R Edmondson, G D Hall, A Clamp, C Gourley, M Hall, C Fotopoulou, H Gabra, S Freeman, L Moore, M Jimenez-Linan, J Paul, J D Brenton and I A McNeish on behalf of the BriTROC investigators18 Br J Cancer 2017 116: 1294-1301; advance online publication, March 30, 2017; 10.1038/bjc.2017.86 Abstract | Full Text Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling Sheng Han, Lingxuan Meng, Yang Jiang, Wen Cheng, Xinxin Tie, Junzhe Xia and Anhua Wu Br J Cancer 2017 116: 1302-1311; advance online publication, March 30, 2017; 10.1038/bjc.2017.89 Abstract | Full Text Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer A Janssen, C P M Verkleij, A van der Vlist, R H J Mathijssen, H J Bloemendal and R ter Heine Br J Cancer 2017 116: 1312-1317; advance online publication, April 11, 2017; 10.1038/bjc.2017.91 Abstract | Full Text Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition George E Duran, Yan C Wang, François Moisan, E Brian Francisco and Branimir I Sikic Br J Cancer 2017 116: 1318-1328; advance online publication, April 11, 2017; 10.1038/bjc.2017.102 Abstract | Full Text Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis William T Tran, Mehrdad J Gangeh, Lakshmanan Sannachi, Lee Chin, Elyse Watkins, Silvio G Bruni, Rashin Fallah Rastegar, Belinda Curpen, Maureen Trudeau, Sonal Gandhi, Martin Yaffe, Elzbieta Slodkowska, Charmaine Childs, Ali Sadeghi-Naini and Gregory J Czarnota Br J Cancer 2017 116: 1329-1339; advance online publication, April 18, 2017; 10.1038/bjc.2017.97 Abstract | Full Text Differential pattern of HIF-1α expression in HNSCC cancer stem cells after carbon ion or photon irradiation: one molecular explanation of the oxygen effect Anne-Sophie Wozny, Alexandra Lauret, Priscillia Battiston-Montagne, Jean-Baptiste Guy, Michael Beuve, Micaela Cunha, Yannick Saintigny, Emilie Blond, Nicolas Magne, Philippe Lalle, Dominique Ardail, Gersende Alphonse and Claire Rodriguez-Lafrasse Br J Cancer 2017 116: 1340-1349; advance online publication, April 13, 2017; 10.1038/bjc.2017.100 Abstract | Full Text Molecular Diagnostics Top Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis Aruz Mesci, Xiaoyong Huang, Samira Taeb, Sahar Jahangiri, Yohan Kim, Emmanouil Fokas, Jeff Bruce, Hon S Leong and Stanley K Liu Br J Cancer 2017 116: 1350-1357; advance online publication, April 18, 2017; 10.1038/bjc.2017.105 Abstract | Full Text Epidemiology Top Serum inflammatory markers and colorectal cancer risk and survival Sundeep Ghuman, Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, Håkan Malmström, Mats Lambe, Niklas Hammar, Göran Walldius, Ingmar Jungner and Wahyu Wulaningsih Br J Cancer 2017 116: 1358-1365; advance online publication, April 4, 2017; 10.1038/bjc.2017.96 Abstract | Full Text Tyrosine kinase-targeting drugs-associated heart failure N Gronich, I Lavi, O Barnett-Griness, W Saliba, D R Abernethy and G Rennert Br J Cancer 2017 116: 1366-1373; advance online publication, April 11, 2017; 10.1038/bjc.2017.88 Abstract | Full Text Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.